Comparative Pharmacology
Head-to-head clinical analysis: FLUTEX versus LEXETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTEX versus LEXETTE.
FLUTEX vs LEXETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flutamide is a nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone (DHT) to androgen receptors in target tissues, thereby blocking the androgenic effects.
LEXETTE (halobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects. The primary mechanism involves binding to glucocorticoid receptors, which modulates gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
50 mg orally once daily
Apply to affected areas once daily for up to 2 weeks. Use no more than 60 g per week.
None Documented
None Documented
Terminal elimination half-life: 24–36 hours, permitting once-daily dosing in chronic therapy
Terminal elimination half-life is 12-15 hours, supporting twice-daily dosing in clinical practice.
Renal: ~70% (50% unchanged, 20% as metabolites); Biliary/fecal: ~30%
Primarily renal excretion of unchanged drug (approximately 70%), with 30% metabolized hepatically via CYP3A4 and excreted as inactive metabolites in urine and feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid